Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Progressive bulbar palsy involves the brain stem. The brain stem is the part of the brain needed for swallowing, speaking, chewing, and other functions. Signs and symptoms of progressive bulbar palsy include difficulty swallowing, weak jaw and facial muscles, progressive loss of speech, and weakening of the tongue. Additional symptoms include less prominent weakness in the arms and legs, and outbursts of laughing or crying (called emotional lability). Progressive bulbar palsy is considered a variant form of amyotrophic lateral sclerosis (ALS). Many people with progressive bulbar palsy later develop ALS. While there is no cure for progressive bulbar palsy or for ALS, doctors can treat symptoms.
Biomarker and diagnostic research for progressive bulbar palsy has been reported in the published literature.
3 clinical trials registered, 1 recruiting. Interventions under study include other interventions. Pipeline includes 2 NA. Research is primarily sponsored by academic and government institutions.
142 publications have been identified in PubMed for progressive bulbar palsy. Research spans Case Report / Case Series (37%), Review / Meta-Analysis (18%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 53 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:18 AM UTC
Genetic and Rare Diseases Info Center
Research summaries | 25 | 18% |
Disease patterns and progression | 23 | 16% |
Laboratory research | 14 | 10% |
Testing and diagnosis research | 11 | 8% |
Clinical study results | 7 | 5% |
New treatment approaches | 7 | 5% |
Other research | 2 | 1% |
Doreswamy K (2026). [PMID: 42127017](https://pubmed.ncbi.nlm.nih.gov/42127017/). *PLOS Digit Health*. [Clinical Trial Publication]
Mehrabian A (2026). [PMID: 41350238](https://pubmed.ncbi.nlm.nih.gov/41350238/). *Annals of clinical and translational neurology*. [Review / Meta-Analysis]
Indelicato E (2026). [PMID: 41738007](https://pubmed.ncbi.nlm.nih.gov/41738007/). *Frontiers in neurology*. [Basic Science / Preclinical]
Kleinerova J (2026). [PMID: 42041816](https://pubmed.ncbi.nlm.nih.gov/42041816/). *Brain Sci*. [Review / Meta-Analysis]
Nakano Y (2026). [PMID: 41815887](https://pubmed.ncbi.nlm.nih.gov/41815887/). *Diabetol Int*. [Case Report / Case Series]
Alam F (2026). [PMID: 41943755](https://pubmed.ncbi.nlm.nih.gov/41943755/). *Cureus*. [Case Report / Case Series]
Warmann S (2026). [PMID: 41714394](https://pubmed.ncbi.nlm.nih.gov/41714394/). *Radiologie (Heidelb)*. [Review / Meta-Analysis]
Keritam O (2026). [PMID: 41513843](https://pubmed.ncbi.nlm.nih.gov/41513843/). *J Neurol*. [Epidemiology / Natural History]
Bernsen S (2026). [PMID: 41482475](https://pubmed.ncbi.nlm.nih.gov/41482475/). *Pract Neurol*. [Case Report / Case Series]
Jellinger KA (2026). [PMID: 40580315](https://pubmed.ncbi.nlm.nih.gov/40580315/). *J Neural Transm (Vienna)*. [Review / Meta-Analysis]